Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

81.50
-1.4400-1.74%
Post-market: 81.500.00000.00%19:30 EDT
Volume:1.74M
Turnover:143.16M
Market Cap:15.96B
PE:-22.84
High:83.37
Open:82.89
Low:81.36
Close:82.94
52wk High:93.42
52wk Low:46.81
Shares:195.81M
Float Shares:154.00M
Volume Ratio:0.63
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-6.34
PE(LYR):-21.53

Loading ...

BridgeBio director Randal W. Scott sells USD 655,873 in common shares

Reuters
·
May 20

BridgeBio Pharma Initiated at Neutral by Citigroup

Dow Jones
·
May 19

U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology

Reuters
·
May 19

BridgeBio initiated with a Neutral at Citi

TIPRANKS
·
May 19

Stock Track | BridgeBio Pharma Soars 5.02% Intraday on Analyst Bullishness

Stock Track
·
May 14

Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI)

TIPRANKS
·
May 13

BridgeBio Oncology Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

BridgeBio Oncology awards employee stock options for 32,675 shares at $7.66

Reuters
·
May 13

BridgeBio shares have ‘clear path’ to $90s, says JPMorgan

TIPRANKS
·
May 12

BRIEF-Bridgebio Submits NDA To FDA For Encaleret For Individuals Living With ADH1

Reuters
·
May 12

BridgeBio Files New Drug Application for Rare Calcium Disorder Treatment

MT Newswires Live
·
May 12

BridgeBio submits FDA NDA for encaleret to treat autosomal dominant hypocalcemia type 1

Reuters
·
May 12

BridgeBio Submits Nda to FDA for Encaleret for Individuals Living With Adh1

THOMSON REUTERS
·
May 12

BridgeBio Pharma Inc - Encaleret May Be Eligible for Priority Review; U.S. Launch Anticipated Early 2027

THOMSON REUTERS
·
May 12

BridgeBio Pharma Inc - to Initiate Phase 3 Reclaim-HP Study of Encaleret in Chronic Hypoparathyroidism Summer 2026

THOMSON REUTERS
·
May 12

BridgeBio Pharma Inc - to Submit Maa to Ema for Encaleret in Adh1 in Second Half 2026

THOMSON REUTERS
·
May 12

BridgeBio publishes Phase 3 CALIBRATE trial presentation for encaleret in ADH1

Reuters
·
May 12

BridgeBio CEO Neil Kumar disposes of common shares worth $5.48 million

Reuters
·
May 12

BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026

TIPRANKS
·
May 12

BridgeBio posts acoramidis ATTRibute-CM KCCQ subgroup data presentation

Reuters
·
May 11